ZYME Stock Recent News

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

Zymeworks is a biotechnology company that develops innovative therapies for difficult-to-treat cancers and serious conditions. The company's flagship drug, Zanidatamab, is in phase 3 clinical trials and has significant market potential for biliary tract cancer. Zymeworks utilizes proprietary platforms to create multispecific antibody therapeutics and antibody-drug conjugate technologies for its drug candidates.

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 2, 2024 at 4:30 pm Eastern Time (ET).

Zymeworks (ZYME) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

Zymeworks (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zymeworks Inc. (NASDAQ:ZYME ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Dr. Chris Astle - Senior Vice President and CFO Paul Moore - Chief Scientific Officer Ken Galbraith - Chair and CEO Conference Call Participants Stephen Willey - Stifel Ivy Wang - Jefferies Yigal Nochomovitz - Citigroup Brian Cheng - JPMorgan Jon Miller - Evercore ISI Operator Thank you for standing by. This is the conference operator.

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to earnings of $4.65 per share a year ago.

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) --  Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024.

Zymeworks' stock has increased by 67% since September, driven by developments in the antibody-drug conjugate sector. The company's lead asset, zanidatamab, is being developed for the treatment of first-line HER2-positive gastroesophageal adenocarcinoma. ZYME has a strong financial position, with a robust liquidity position and a cash runway that extends into 2027.